• Zhihong Li, Qingwang Liu, Junchao Yao, and Xiang Zhang.
• Department 5 of Neurosurgery, Cangzhou Central Hospital, Cangzhou, Hebei, China. Electronic address: czszxyylzh@163.com.
• World Neurosurg. 2022 Dec 1; 168: e570e577e570-e577.

BackgroundIntracranial aneurysm (IA) has been identified in approximately 0.4%-3% of the population and associated with 3%-10% mortality. IA is the major factor attributing to spontaneous subarachnoid hemorrhage. We aim to investigate that whether employing dexmedetomidine (DEX), an α2 adrenergic receptor agonist, as a supplementation could impact the outcomes of patients with intracranial interventional embolization.MethodsPatients were randomly divided into a control group (n = 48 cases) and a DEX (0.6 μg/kg) supplement group (n = 48 cases). Patients' outcomes were evaluated using the Glasgow Outcome Scale. Serum levels of norepinephrine, cortisol, interleukin-6, C-reactive protein, neuron-specific enolase, and S100β were determined using enzyme-linked immunoassay. The cognitive function of patients was assessed using the Mini-Mental State Exam and Montreal Cognitive Assessment tests.ResultsDEX supplementation during anesthesia reduced adverse reaction, surgical stress, and attenuated cognitive impairment after extubation in IA patients' postintracranial interventional embolization.ConclusionsOur study demonstrated that employing DEX as supplementation during anesthesia could effectively reduce surgical stress and improve cognitive function, ultimately improving patients' recovery from intracranial interventional embolization.Copyright © 2022 Elsevier Inc. All rights reserved.

12 keywords...

hide…